DMRA

23.2404.36%
ML

Michael Landsittel

Independent Director

Mr. Michael Landsittel, also known as Mike, is Independent Director of Remix Therapeutics, Inc. from October 2026. Mr. Landsittel serves as an Independent Director of Damora Therapeutics, Inc. from March 2026. Mr. Landsittel has broad biotech experience spanning strategic finance, corporate and business development, investor relations and organizational leadership. He had been Chief Financial Officer of Blueprint Medicines Corporation since January 30, 2019. He served as Vice President of Finance at Blueprint Medicines Corporation since February 2016 until January 2019. Mr. Landsittel served as a Senior Director of Finance at Blueprint Medicines Corporation from September 2014 to February 2016. Mr. Landsittel served as Senior Director, Finance at Algeta from October 2012 to July 2014, as Director, Finance at Infinity Pharmaceuticals, Inc. from March 2012 to October 2012 and held various business development and strategic planning roles of increasing responsibility at Genzyme from August 2002 to March 2012. Mr. Landsittel began his career at Arthur Andersen LLP and he earned his certified public accountant license in Illinois. Mr. Landsittel received a B.B.A. from the University of Michigan and an M.B.A. from the Tuck School of Business at Dartmouth College.

Positions